Valuation: Opus Genetics, Inc.

Market Cap 396M 348M 328M 299M 560M 37.96B 564M 3.93B 1.52B 19.39B 1.49B 1.45B 62.32B P/E 2026 *
-4.86x
P/E 2027 * -6.72x
Enterprise Value 396M 348M 328M 299M 560M 37.96B 564M 3.93B 1.52B 19.39B 1.49B 1.45B 62.32B EV / Sales 2026 *
30.2x
EV / Sales 2027 * 29.1x
Free-Float
87.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day-2.26%
1 week-8.11%
Current month+31.49%
1 month+15.82%
3 months+27.96%
6 months+0.21%
Current year+136.82%
1 week 4.6
Extreme 4.6
5.55
1 month 3.51
Extreme 3.511
7.07
Current year 1.88
Extreme 1.88
7.07
1 year 1.5
Extreme 1.5
7.07
3 years 0.65
Extreme 0.65
7.07
5 years 0.65
Extreme 0.65
7.07
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 A Exercice

Chief Executive Officer

859,855 1.0335%
9/8/26 A Exercice

Chairman

1,568,628 1.8855%
9/3/26 A Sell

Chief Financial Officer

-28,000 0.0337%
Change 5-day change 1-year change 3-year change Capi.($)
-2.26%-8.11%+176.74%+22.05% 397M
+0.13%+2.65%+65.61%+114.28% 1,055B
+0.20%+0.46%+52.60%+69.24% 654B
-0.29%+0.14%+20.96%+70.93% 467B
-0.85%+0.98%+41.29%+44.38% 348B
+0.71%+4.08%+22.24%+29.51% 275B
+1.23%+0.42%+14.57%+12.13% 258B
+2.11%+7.51%+52.89%+55.37% 224B
+0.83%+0.55%+35.99%+101.70% 187B
0.00%-10.14%-29.94%-60.30% 171B
Average +0.10%-0.15%+45.30%+45.93% 363.88B
Weighted average by Cap. +0.02%+1.32%+41.55%+67.83%

Financials

2026 *2027 *
Net sales 13.11M 11.51M 10.87M 9.9M 18.54M 1.26B 18.67M 130M 50.36M 642M 49.23M 48.16M 2.06B 13.59M 11.93M 11.27M 10.27M 19.22M 1.3B 19.36M 135M 52.22M 666M 51.04M 49.94M 2.14B
Net income -91.93M -80.67M -76.19M -69.43M -130M -8.81B -131M -912M -353M -4.5B -345M -338M -14.47B -68.94M -60.5M -57.14M -52.07M -97.47M -6.61B -98.17M -684M -265M -3.38B -259M -253M -10.85B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
25/09/26 $4.760 -2.26% 1,244,934
24/09/26 $4.870 +0.83% 1,831,216
23/09/26 $4.830 -6.40% 3,055,680
22/09/26 $5.160 -1.15% 1,172,556
21/09/26 $5.220 +0.77% 1,980,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4.760USD
Average target price
13.00USD
Spread / Average Target
+173.11%

Quarterly revenue - Rate of surprise